Moreover, in the in vivo animal experiment, a decrease in Foxj2 levels was observed in the pathological process of several inflammation‐related diseases, including HFD‐induced obesity, NAFLD, Dox‐induced cardiomyopathy, AMI and D‐gal induced aging conditions, suggesting that Foxj2 may play diverse and potentially context‐specific roles in various inflammatory diseases. This evidence concerns the gene FOXJ2 and metabolic dysfunction-associated steatotic liver disease.